Biopharma Quarterly Dealmaking Statistics, Q3 2016
A look at financing, M&A and alliance activity July–September 2016
Executive Summary
In Q3, biopharma financing totaled $7.4 billion, a large proportion of which was by rare disease developers; among the highlights in the $23 billion in M&As was Allergan's buying spree, including two NASH companies. Just over $20 billion went into biopharma alliance dealmaking, and neurology assets attracted many of the dollars.